New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2014
06:10 EDTOCROmnicare upgraded to Buy from Neutral at UBS
UBS upgraded Omnicare due to valuation and said it now believes there is a large generic Namenda XR opportunity in 2016. Price target is $64.
News For OCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for OCR

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use